![Marc Dechamps](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profilo
Marc Dechamps is Chief Executive Officer at Bioxodes SA since 2022.
Mr. Dechamps is Independent Director at OSE Immunotherapeutics SA since 2024.
Formerly, Mr. Dechamps was Co-Managing Director at Catalent Gosselies PS SA. Mr. Dechamps was Director & Head-Business Development at eTheRNA immunotherapies NV.
Posizioni attive di Marc Dechamps
| Società | Posizione | Inizio |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Direttore/Membro del Consiglio | 19/06/2024 |
Bioxodes SA
 Bioxodes SA BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapeutics targeting thrombo-inflammation | Amministratore Delegato | 01/10/2022 |
Precedenti posizioni note di Marc Dechamps
| Società | Posizione | Fine |
|---|---|---|
Delphi Genetics SA
 Delphi Genetics SA BiotechnologyHealth Technology Develops DNA applications for bio-productions | Amministratore Delegato | 01/07/2017 |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
26
Relazioni di 1° grado
4
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
Delphi Genetics SA
Delphi Genetics SA BiotechnologyHealth Technology Develops DNA applications for bio-productions | Health Technology |
Bioxodes SA
Bioxodes SA BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapeutics targeting thrombo-inflammation | Health Technology |
OSE Immunotherapeutics SA
 OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Health Technology |
